Company Overview
Nkarta, Inc. operates as a clinical-stage biopharmaceutical company focused on the development and commercialization of natural killer cell therapies designed for the treatment of cancer and autoimmune diseases. The company functions within the broader Healthcare sector, specifically inside the Biotechnology industry, positioning it as a specialized entity engaged in high-risk, high-reward drug discovery and potential commercialization phases. As of the latest available data, the company holds a market capitalization of $151.29M and employs a workforce of 105 individuals dedicated to its research and development efforts. The combination of a market cap under $200M and a revenue figure that is currently unreported (N/A) indicates that Nkarta is an early-stage biotechnology firm where value is derived primarily from intellectual property and clinical progress rather than established sales streams, reflecting the typical capital-intensive nature of clinical-stage development before product approval.
Financial Health
The company reported a net income of $-102,610,000 and an EBITDA of $-106,944,000 over the trailing twelve months, while revenue figures are not yet available for reporting. The substantial gap between the reported net income and EBITDA, alongside the absence of revenue, reveals a cost structure dominated by research and development expenses that have not yet been offset by commercial sales. Free cash flow stands at $-57,524,000, which signifies that the company is currently consuming cash reserves to fund its operations and clinical trials rather than generating surplus liquidity for shareholders. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that accurately reflects the company's status as a pre-revenue entity where no gross profit has been realized to date. On the balance sheet, the company holds $282.33M in cash against $76.63M in debt, resulting in a debt-to-equity ratio of 22.68, which suggests a balance sheet that is leveraged but heavily weighted toward cash assets. The current ratio is listed at 15.23, indicating an extremely robust position regarding short-term liquidity where current assets significantly exceed current liabilities. Return on Equity is -26.7% and Return on Assets is -15.1%, metrics that reveal management is currently utilizing equity and asset bases to generate losses rather than profits, a common characteristic for clinical-stage biotechs still in the investment phase.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed at -1.16, implying that analysts project continued negative earnings or that the stock is priced based on alternative metrics given the company's financial stage. The price-to-book ratio is 0.45, indicating that the market values the company at less than half of its book value, which suggests the market is pricing in significant risks associated with clinical trial failure or the long timeline required for regulatory approval. Alternative valuation metrics such as the price-to-sales ratio are N/A, and the EV/EBITDA stands at 0.51, suggesting that the enterprise value is very low relative to earnings before interest, taxes, depreciation, and amortization, though this metric is often less reliable for unprofitable companies with no sales. The stock's price range over the last year has oscillated between a 52-week high of $2.81 and a 52-week low of $1.31, providing a context for understanding the stock's recent trading volatility. The beta value is 0.57, which indicates that the stock's price volatility is historically lower than the broader market, moving with less intensity than the general equity index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data to compare growth rates as the company has not yet transitioned to a revenue-generating phase. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate, and the payout ratio is recorded at 0.0%, reflecting the standard practice for clinical-stage firms that reinvest all available capital into research, development, and clinical trials rather than distributing income. The absence of a dividend yield confirms that the company follows a growth-at-all-costs strategy typical of biotechnology firms seeking to advance their lead product candidate, NKX019, through clinical validation. The overall growth and income profile is currently defined by a lack of revenue generation and a complete absence of dividend income, focusing entirely on capital deployment toward future clinical milestones.